In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy showed a 60.9% overall response rate, outperforming the 40% ...

as well as an increase in overall survival (OS), when used as a first-line treatment for colorectal cancer with BRAF V600E mutations. Both results were "clinically meaningful," according to a ...

Two months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer ... people diagnosed with bowel cancer who have a BRAF V600E mutation are currently extremely ...

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6. Among patients with metastatic colorectal cancer ...

Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo significantly improved PFS and OS in colorectal cancer with BRAF V600E mutation. The regimen demonstrated a 60.9% confirmed ORR ...

“These data from the BREAKWATER study show the potential for this targeted treatment regimen to become the new standard of care for people with BRAF V600E -mutant metastatic colorectal cancer, for ...

The Braftovi combination regimen received accelerated approval by the FDA in December 2024 for treatment-naive patients with BRAF V600E-mutant mCRC based on a clinically meaningful and ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has ... the combination in mCRC patients living with a BRAF V600E mutation who are treatment-naive. The top-line data also ...